atropine + leukotriene D4

This is a combination of two agents, atropine and leukotriene D4, which are not known to be co-formulated as a pharmaceutical product but have been studied together in experimental settings. Atropine is a well-established antimuscarinic (anticholinergic) agent that blocks muscarinic acetylcholine receptors, leading to effects such as bronchodilation and reduced secretions. Leukotriene D4 (LTD4) is an endogenous inflammatory mediator belonging to the cysteinyl leukotrienes family; it acts primarily via the cysteinyl leukotriene receptor 1 (CysLT1), causing potent bronchoconstriction and increased vascular permeability in airways. Experimental studies show that LTD4 can potentiate histamine-induced bronchoconstriction, an effect that can be prevented by atropine administration—suggesting interaction between cholinergic pathways and leukotriene-mediated responses[1][6]. Atropine’s antagonism of muscarinic receptors may counteract some of the bronchoconstrictive effects induced by LTD4.